SHR 3167
Alternative Names: SHR-3167Latest Information Update: 16 Jun 2026
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus
- Phase I Diabetes mellitus
Most Recent Events
- 22 Apr 2026 Jiangsu HengRui Medicine completes a phase II trial in Type 2 diabetes mellitus (Treatment experienced) in China (SC) (NCT06688123)
- 11 Apr 2026 Jiangsu HengRui Medicine initiates enrolment in a phase II trial for Type 2 diabetes mellitus (Treatment-experienced) in China (Parenteral, injection) (NCT07472725)
- 02 Apr 2026 Jiangsu HengRui Medicine initiates a phase I trial for Diabetes mellitus (In volunteers) in China (Injection) (NCT07489482)